The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study

Tarek M Mostafa, Gamal A El-Azab, Ghada A Atia, Noran S Lotfy, Tarek M Mostafa, Gamal A El-Azab, Ghada A Atia, Noran S Lotfy

Abstract

Background: There are differences of opinion about both the most effective combined therapeutic strategy and the clinical benefit of inhaled corticosteroids in nonasthmatic patients with chronic obstructive pulmonary disease. Furthermore, many inflammatory cytokines are reportedly correlated with severity of the disease.

Objectives: To compare the effectiveness of long acting β-agonist + long-acting muscarinic antagonist (LABA + LAMA) versus LABA + inhaled corticosteroid and LAMA + inhaled corticosteroid in nonasthmatic patients with moderate-to-severe chronic obstructive pulmonary disease. To assess the changes that occurred in plasma concentrations of tumor necrosis factor α, fibrinogen, and interleukin 6, and correlate these with disease activity.

Methods: In this pilot study, 45 nonasthmatic patients with moderate to severe chronic obstructive pulmonary disease were randomized into 3 groups with 15 patients in each group. Group I (LABA + inhaled corticosteroid) received formoterol/budesonide, group II (LAMA + inhaled corticosteroid) received tiotropium/budesonide and group III (LABA + LAMA) received formoterol/tiotropium for 12 weeks. Patients were assessed initially and then at 4 and 12 weeks by measuring the changes that occurred in forced expiratory volume in 1 second as a percent of predicted and in the modified Medical Research Council dyspnea scale. Plasma concentrations of tumor necrosis factor α, fibrinogen, and interleukin 6 were simultaneously measured.

Results: The 3 study groups were statistically similar with respect to their demographic data and disease characteristics. All therapeutic options produced an improvement in forced expiratory volume in 1 second as a percent of predicted and in the modified Medical Research Council dyspnea scale as well as a reduction in plasma concentrations of the inflammatory markers. The effects produced by the three therapeutic combinations on forced expiratory volume in 1 second as a percent of predicted, plasma tumor necrosis factor α, interleukin 6, and fibrinogen concentrations were statistically similar after 4 and 12 weeks (4 weeks after treatment: P = 0.358, P = 0.284, P = 0.155, and P = 0.155, respectively, and 12 weeks after treatment: P = 0.710, P = 0.773, P = 0.240, and P = 0.076, respectively).

Conclusions: In nonasthmatic patients with moderate to severe chronic obstructive pulmonary disease, the 3 therapeutic combinations showed similar effectiveness. The results of this pilot study also suggest that inflammatory markers can be used to track disease activity. Clinicaltrials.gov identifier: NCT04520230. (Curr Ther Res Clin Exp. 2021; 82:XXX-XXX).

Keywords: COPD; Fibrinogen; ICS; LABA; LAMA; TNF-ɑ.

Conflict of interest statement

The authors have indicated that they have no conflicts of interest regarding the content of this article.

© 2021 The Authors.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Flow chart illustrating the participant screening, enrollment, and randomization. ICS = inhaled corticosteroid; LABA = long-acting β-agonist; LAMA = long-acting muscarinic antagonist.

References

    1. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. (2018). Available at: (accessed November 20, 2018).
    1. Alagha K, Palot A, Sofalvi T, Pahus L, Gouitaa M, Tummino C, Martinez S, Charpin D, Bourdin A, Chanez P. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases Ther Adv Chronic Dis. 2014;5(2):85-98. doi:10.1177/2040622313518227.
    1. Billington CK, Ojo OO, Penn RB, Ito S. cAMP regulation of airway smooth muscle function. Pulm Pharmacol Ther. 2013;26(1):112–120. doi: 10.1016/j.pupt.2012.05.007.
    1. Anderson R, Theron AJ, Steel HC, Durandt C, Tintinger GR, Feldman C. The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro. Mediators Inflamm. 2014;2014 doi: 10.1155/2014/105420.
    1. Benfante A, Braido F, Scichilone N. The anti-inflammatory properties of tiotropium. Lancet Respir Med. 2018;6(8):e37. doi: 10.1016/S2213-2600(18)30190-5.
    1. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med. 2010;16(2):97–105. doi: 10.1097/MCP.0b013e328335df1e.
    1. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149. doi: 10.1186/1465-9921-11-149.
    1. Barnes PJ. Inhaled corticosteroids are not helpful in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(2 Pt 1):342–344. doi: 10.1164/ajrccm.161.2.16125_2.
    1. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J. 2009;34(1):13–16. doi: 10.1183/09031936.00190908.
    1. Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration. 2010;80(2):89–95. doi: 10.1159/000315416.
    1. Burge PS, Calverley PM, Jones PW. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303. doi: 10.1136/bmj.320.7245.1297.
    1. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008:2407–2416. doi: 10.1001/jama.2008.717.
    1. Pauwels RA, Lofdahl CG, Laitinen LA. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340:1948–1953. doi: 10.1056/NEJM199906243402503.
    1. Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;(2) doi: 10.1002/14651858.CD002991.
    1. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNF alpha in pulmonary pathophysiology. Respir Res. 2006;7(1):125. doi: 10.1186/1465-9921-7-125.
    1. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, Lomas DA. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013;68(7):670–676. doi: 10.1136/thoraxjnl-2012-201871.
    1. He JQ, Foreman MG, Shumansky K, Zhang X, Akhabir L, Sin DD, Man SF, DeMeo DL, Litonjua AA. Associations of IL-6 polymorphisms with lung function decline and COPD. Thorax. 2009;64(8):698–704. doi: 10.1136/thx.2008.
    1. Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K, Kaneko T. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2(2):CD012066. doi: 10.1002/14651858.CD012066.pub2.
    1. Vestbo J, Rennard S. Chronic obstructive pulmonary disease biomarker(s) for disease activity needed—urgently. Am J Respir Crit Care Med. 2010;182:863–864. doi: 10.1164/rccm.201004-0602ED.
    1. Julious Steven A. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceut Statist. 2005;4(4) doi: 10.1002/pst.185. 287 - 291.
    1. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med. 1995;89(5):357–362. doi: 10.1016/0954-6111(95)90008-x.
    1. Banerji D, Patalano F. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2016;110:79–80. doi: 10.1016/j.rmed.2015.07.009.
    1. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63:402–407. doi: 10.1136/thx.2007.085456.
    1. Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT) Respir Med. 2010;104(11):1659–1667. doi: 10.1016/j.rmed.2010.07.016.
    1. Martinez CH, Diaz AA, Parulekar AD, Rennard SI, Kanner RE, Hansel NN, Couper D, Holm KE, Hoth KF, Curtis JL, Martinez FJ, Hanania NA, Regan EA, 3rd Paine R, Cigolle CT, Han MK, Gene COPD, Investigators SPIROMICS. Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts. Chest. 2016;149(4):927–935. doi: 10.1016/j.chest.2015.11.025.
    1. Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov. 2004;3(9):801–808. doi: 10.1038/nrd1500.
    1. Cazzola M, Calzetta L, Ora J. Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside. Respir Med. 2015;109(10):1305–1311. doi: 10.1016/j.rmed.2015.08.005.
    1. Um SW, Yoo CG, Kim YW, Han SK, Shim YS. The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease. J Korean Med Sci. 2007;22(5):839–845. doi: 10.3346/jkms.2007.22.5.839.
    1. Loppow D, Schleiss MB, Kanniess F, Taube C, Jörres RA, Magnussen H. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med. 2001;95(2):115–121. doi: 10.1053/rmed.2000.0960.
    1. Haque R, Hakim A, Moodley T, Torrego A, Essilfie-Quaye S, Jazrawi E. Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD. J Allergy Clin Immunol. 2013;132(5):1166–1173. doi: 10.1016/j.jaci.2013.07.038.
    1. Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, Adcock IM. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005;172(6):704–712. doi: 10.1164/rccm.200408-1041OC.
    1. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J. 2002;19(1):182–191. doi: 10.1183/09031936.02.00283202.
    1. Miravitlles M, Soler-Cataluña JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J. 2013;41(6):1252–1256. doi: 10.1183/09031936.00118912.
    1. Tamimi A, Serdarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med. 2012;106(3):319–328. doi: 10.1016/j.rmed.2011.11.003.
    1. Suissa S, Dell'Aniello S, Ernst P. Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. Chest. 2019;155(6):1158–1165. doi: 10.1016/j.chest.2019.03.005.
    1. Mahler DA, Witek TJ., Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD. 2005;2(1):99–103. doi: 10.1081/COPD-200050666.
    1. Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study) Int J Chron Obstruct Pulmon Dis. 2016;11:193–205. doi: 10.2147/COPD.S95055.
    1. Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis Int J Chron Obstruct Pulmon Dis. 2017;12:907-922. doi: 10.2147/COPD.S130482. eCollection 2017
    1. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15–25. doi: 10.1136/thoraxjnl-2014-206732.
    1. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5) doi: 10.2165/00003495-200969050-00004. 549-465.
    1. Huang AX, Lu LW, Liu WJ, Huang M. Plasma Inflammatory Cytokine IL-4, IL-8, IL-10, and TNF-α Levels Correlate with Pulmonary Function in Patients with Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Syndrome. Med Sci Monit. 2016;22:2800–2808. doi: 10.12659/msm.896458.
    1. Barnes PJ. Emerging pharmacotherapies for COPD. Chest. 2008;134(6):1278–1286. doi: 10.1378/chest.08-1385.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다